We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.97%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$815M
AUM Growth
+$105M
Cap. Flow
+$27.8M
Cap. Flow %
3.41%
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
36
Reduced
33
Closed
18

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$22.9M
2
SDGR icon
Schrodinger
SDGR
+$16.6M
3
FTRE icon
Fortrea Holdings
FTRE
+$14.8M
4
OSCR icon
Oscar Health
OSCR
+$11.4M
5
HCA icon
HCA Healthcare
HCA
+$10.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
BSX icon
Boston Scientific
BSX
+$14.6M
3
KROS icon
Keros Therapeutics
KROS
+$10.8M
4
MTD icon
Mettler-Toledo International
MTD
+$9.1M
5
HUM icon
Humana
HUM
+$8.28M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Industrials 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
76
DELISTED
Amicus Therapeutics
FOLD
$2.67M 0.33%
+226,723
New +$2.9M
INSM icon
77
Insmed
INSM
$28.9B
$2.52M 0.31%
93,032
-57,784
-38% -$1.62M
SIBN icon
78
SI-BONE Inc
SIBN
$852M
$2.5M 0.31%
152,781
+7,206
+5% +$136K
ANNX icon
79
Annexon
ANNX
$873M
$2.49M 0.31%
+346,687
New +$1.8M
VKTX icon
80
Viking Therapeutics
VKTX
$3.97B
$2.48M 0.3%
+30,298
New +$1.35M
TGTX icon
81
TG Therapeutics
TGTX
$7.58B
$2.36M 0.29%
155,039
-50,278
-24% -$801K
ABOS icon
82
Acumen Pharmaceuticals
ABOS
$181M
$2.34M 0.29%
576,657
-26,840
-4% -$101K
YARW
83
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$2.14M 0.26%
13,929
– –
EPIX
84
DELISTED
ESSA Pharma
EPIX
$2.14M 0.26%
+251,695
New +$2.2M
ETNB
85
DELISTED
89bio
ETNB
$2.09M 0.26%
179,899
-39,549
-18% -$438K
RVPH
86
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$1.9M 0.23%
+25,193
New +$2M
CDMO
87
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$1.81M 0.22%
+270,136
New +$1.86M
INZY
88
DELISTED
Inozyme Pharma
INZY
$1.71M 0.21%
222,943
+10,511
+5% +$57.7K
ARDX icon
89
Ardelyx
ARDX
$1.03B
$1.46M 0.18%
+200,000
New +$1.71M
CYTK icon
90
Cytokinetics
CYTK
$10.5B
$1.41M 0.17%
+20,160
New +$1.56M
XFOR icon
91
X4 Pharmaceuticals
XFOR
$425M
$1.12M 0.14%
26,845
+1,267
+5% +$35.3K
SOPH icon
92
SOPHiA GENETICS
SOPH
$635M
$1.03M 0.13%
209,896
+9,899
+5% +$47.8K
BFLY icon
93
Butterfly Network
BFLY
$2.52B
$810K 0.1%
+750,000
New +$804K
TKNO icon
94
Alpha Teknova
TKNO
$397M
$785K 0.1%
296,202
+13,966
+5% +$43.3K
NVCR icon
95
NovoCure
NVCR
$2.05B
$782K 0.1%
+50,000
New +$735K
ETON icon
96
Eton Pharmaceutcials
ETON
$1.14B
$747K 0.09%
199,168
– –
TELA icon
97
TELA Bio
TELA
$32.3M
$554K 0.07%
97,668
-5,707
-6% -$37.6K
THRD
98
DELISTED
Third Harmonic Bio
THRD
$378K 0.05%
+40,000
New +$389K
XERS icon
99
Xeris Biopharma Holdings
XERS
$1.55B
$222K 0.03%
+100,676
New +$260K
AMGN icon
100
Amgen
AMGN
$225B
– –
-61,524
Closed -$17.7M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Parkman Healthcare Partners held 117 positions worth $815M, up 15% from $710M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners deployed $27.8M of net new capital in Q1 2024, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was Eli Lilly: 32,117 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $14.6M trimmed.

  • Parkman Healthcare Partners's largest Q1 2024 buy was Eli Lilly: 32,117 shares worth $25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q1 2024, an estimated $16.6M increase.
  • Parkman Healthcare Partners's biggest Q1 2024 reduction was Boston Scientific, cutting an estimated $14.6M.
  • Parkman Healthcare Partners fully exited Amgen in Q1 2024, selling an estimated $17.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $815M portfolio in Q1 2024.
  • Parkman Healthcare Partners opened 28 new positions and closed 18 in Q1 2024.
  • Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $815M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.